Reactive thrombocytocis
Reading File
Finding Sources
Finding Sources
Searching PubMed
reactive thrombocytosis secondary thrombocytosis
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Excellent - I now have the key comparison table and comprehensive content. Let me compile the full answer.
Reactive Thrombocytosis (Secondary Thrombocytosis)
Definition
Thrombocytosis is defined by the WHO as a platelet count >450 × 10⁹/L. Reactive (secondary) thrombocytosis is an elevation in platelet count driven by an underlying systemic condition, as opposed to primary (clonal) thrombocytosis arising from autonomous bone marrow disorders (MPNs, myelodysplastic syndrome).
- Washington Manual of Medical Therapeutics, p. 764
- Henry's Clinical Diagnosis and Management by Laboratory Methods
Pathogenesis
In most patients, thrombocytosis is acquired. The rare inherited forms result from gain-of-function mutations in thrombopoietin (TPO) or its receptor (MPL). In reactive thrombocytosis, the platelet count rises in response to:
- Cytokines (particularly interleukins such as IL-6) released during inflammation or tissue injury, which stimulate megakaryocyte proliferation via TPO
- Reduced splenic sequestration (post-splenectomy) - platelets that would normally pool in the spleen are released into circulation
- Iron deficiency - the mechanism is incompletely understood but may involve uncoupled megakaryocyte maturation
Causes
| Category | Examples |
|---|---|
| Infection / Inflammation | Sepsis, osteomyelitis, rheumatoid arthritis, IBD, Kawasaki disease |
| Iron deficiency anemia | Most common cause in children |
| Malignancy | Solid tumors (especially GI, lung, ovarian) |
| Post-splenectomy | Persistent; platelets no longer pooled in spleen |
| Tissue damage / Trauma | Surgery, burns, fractures |
| Hemolysis | Hemolytic anemias |
| Rebound thrombocytosis | Recovery from thrombocytopenia (alcohol withdrawal, B12/folate repletion, after chemotherapy) |
- Quick Compendium of Clinical Pathology, p. 239
- Washington Manual, p. 764
Clinical Features and Risk
A key distinguishing point from clonal thrombocytosis:
No increased risk of thrombosis or hemorrhage in reactive thrombocytosis, even at very high platelet counts.
However, one important exception: reactive thrombocytosis occurring during ICU recovery has been associated with an increased incidence of venous thromboembolism (~10% of cases) - particularly when additional risk factors (malignancy, immobility, central catheters) are present. - Henry's, citing Ho et al., 2012
There is no splenomegaly, no erythromelalgia, and no microvascular ischemia.
Distinguishing Reactive vs. Clonal Thrombocytosis
| Finding | Clonal Thrombocytosis (ET/MPN) | Reactive Thrombocytosis |
|---|---|---|
| Underlying systemic disease | No | Often clinically apparent |
| Digital / cerebrovascular ischemia | Characteristic | No |
| Large-vessel thrombosis | Increased risk | No |
| Bleeding complications | Increased risk | No |
| Splenomegaly | ~40% of patients | No |
| Peripheral blood smear | Giant, abnormal platelets | Normal platelets |
| Platelet function | May be abnormal | Normal |
| BM megakaryocytes (morphology) | Giant, dysplastic, increased ploidy | Normal morphology |
| JAK2/CALR/MPL/BCR-ABL1 mutations | Present | Absent |
Modified from Schafer AI, N Engl J Med 2004; as cited in Henry's Clinical Diagnosis and Management
Laboratory Findings
- Elevated platelet count (may be markedly elevated, >1000 × 10⁹/L in extreme cases)
- Peripheral smear: normal platelet morphology (no giant or dysplastic platelets)
- No clonal markers: JAK2 V617F, CALR, MPL mutations are absent
- May show features of underlying cause: elevated CRP/ESR (inflammation), low ferritin/microcytic anemia (iron deficiency), leukocytosis (infection)
- Platelet function tests: normal
- Bone marrow (if done): increased megakaryocytes with normal morphology (contrast with ET where giant dysplastic megakaryocytes are seen)
Note: Extreme thrombocytosis (>1000 × 10⁹/L) can occur in both reactive and clonal etiologies - the platelet count alone is not a reliable discriminator.
Management
- Treat the underlying cause - platelet count normalizes once the causative condition resolves
- No cytoreductive therapy is needed for reactive thrombocytosis
- If thrombotic complications occur despite a reactive picture, reassess for an occult MPN
- Post-splenectomy thrombocytosis is typically persistent but benign; low-dose aspirin is sometimes used empirically
Diagnosis of Essential Thrombocythemia (ET) by Exclusion
For ET diagnosis (WHO 2016 criteria), all four must be met:
- Platelet count ≥450 × 10⁹/L
- BM biopsy: increased mature megakaryocytes, no excess erythropoiesis or granulopoiesis, no reticulin >grade I
- Exclusion of BCR-ABL1+ CML, PV, myelofibrosis, MDS
- JAK2 V617F, CALR, or MPL mutation present - OR if absent, no evidence for reactive thrombocytosis
This means reactive thrombocytosis must be actively excluded before diagnosing ET.
- Washington Manual, p. 764-765
This is a shared conversation. Sign in to Orris to start your own chat.